MedTrace Logo

The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis

NCT00917020 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2012-08-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of as-needed treatment with nasal carbon dioxide in patients with Seasonal Allergic Rhinitis symptoms.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

Nasal CO2

As-Needed during the 14 day Treatment Period

DRUG

Inactive Placebo Gas

Placebo

Sponsors & Collaborators

  • Capnia, Inc.

    lead INDUSTRY

Principal Investigators

  • Anish Bhatnagar, MD · Capnia, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-10-31
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00917020 on ClinicalTrials.gov